Allergen immunotherapy (AIT) has gained a permanent place in the
therapeutic arsenal for the patient with allergy. Particularly,
substantial evidence has been established for the efficacy of AIT in
allergic rhinitis. A hallmark of AIT is it disease modifying effect
resulting in persistent benefit after the treatment has been terminated.
Both the subcutaneous and sublingual mode of administration appear to be
safe. It is, however, a matter of debate whether AIT can be implemented
for patients with asthma. EAACI and GINA guidelines recommend sublingual
AIT in house dust mite driven asthma. The question however remains
whether the different available forms of AIT should be used for allergic
asthma in general.